Clinical trials: Moderate to Severe Chronic Pain
Pain
Oxycodone-naloxone in Relieving Opioid-related Constipation
The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects…
- Trial name
- NCT00412152
- Testing
- Oxycodone nalaxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Lower Back Pain
Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001.
- Trial name
- NCT07122453
- Testing
- CNTX-3001
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Centrexion Therapeutics
Pain, Chronic Back Pain
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
The purpose of this study is to evaluate tapentadol Extended Release (ER) in the treatment of moderate to severe chronic pain in participants with a diagnosis of chronic low back pain (LBP) or osteoarthritis (OA) of the hip or…
- Conditions
- Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
- Trial name
- NCT01631513
- Testing
- Nucynta ER
- Where
- 7 sites in United States
- Sponsor
- Janssen Scientific Affairs, LLC
Osteoarthritis, Knee, Knee Pain Chronic
A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
This study evaluates the efficacy and safety of intra-articular injection of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.
- Trial name
- NCT04044742
- Testing
- Resiniferatoxin
- Sponsor
- Sorrento Therapeutics, Inc.
Pain
Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with…
- Trial name
- NCT00278824
- Testing
- Matrix Transdermal Fentanyl/CHADD Drug Delivery System
- Where
- 15 sites in United States
- Volunteers
- 109 people
- Sponsor
- ZARS Pharma Inc.
Pain, Neoplasm
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
- Conditions
- Pain, Neoplasm, Cancer
- Trial name
- NCT00505414
- Testing
- Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Tapentadol in the Maintenance Phase
- Where
- 37 sites in United States, Argentina and 4 more
- Volunteers
- 136 people
- Sponsor
- Grünenthal GmbH
Chronic Pain
A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.
The purpose of this study is to assess the safety of tramadol HCl ER following long-term treatment. The study hypothesis is that long-term treatment with tramadol HCl ER is safe and effective for the treatment of chronic…
- Trial name
- NCT00347685
- Testing
- tramadol ER
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Pain, Osteoarthritis of the Knee
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic pain due to…
- Trial name
- NCT00531427
- Testing
- Buprenorphine
- Where
- 87 sites in United States
- Volunteers
- 567 people
- Sponsor
- Purdue Pharma LP
Chronic Prostatitis
TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS
This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
- Trial name
- NCT06287970
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Jiani Wu
Chronic Low Back Pain
Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain
The purpose of this study is to determine the efficacy and safety of EN3324 (axomadol) in subjects with moderate to severe chronic low back pain
- Trial name
- CLBP (NCT01043263)
- Testing
- EN3324 (axomadol)
- Where
- 59 sites in United States
- Volunteers
- 236 people
- Sponsor
- Grünenthal GmbH
Osteoarthritis, Knee, Pain
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
- Trial name
- NCT01688934
- Testing
- V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules
- Where
- 18 sites in United States
- Volunteers
- 230 people
- Sponsor
- Purdue Pharma LP
Stump Pain
Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain
Primary: To compare the analgesic effect over 12 weeks of topical 2PX in stump pain. Secondary: To prospectively measure other efficacy and safety variables of topical 2PX in stump pain.
- Trial name
- NCT00804375
- Testing
- 2PX
- Where
- 19 sites in Denmark, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Smerud Medical Research International AS
Cancer Pain
A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain
This is a randomised, active-controlled, double-blind, double-dummy, parallel group study with BUP TDS 20 mg (release rate 35 µg/h), 30 mg (release rate 52.5 µg/h) and 40 mg (release rate 70 µg/h), and MOR SR 60 mg, 100 mg or 120…
- Trial name
- NCT03967327
- Testing
- Buprenorphine transdermal patches, Morphine Sulfate Sustained-Release Tablet
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain, Low Back Pain
Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain
The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.
- Conditions
- Pain, Low Back Pain, Osteoarthritis, Neuropathic Pain
- Trial name
- NCT01298765
- Testing
- BEMA Buprenorphine
- Where
- 26 sites in United States
- Volunteers
- 302 people
- Sponsor
- BioDelivery Sciences International
Chronic Low Back Pain
Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)
The purpose of this study is to evaluate the analgesic efficacy of Oxycodone DETERx compared with placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe chronic low back pain requiring around-the-clock…
- Trial name
- NCT01685684
- Testing
- Oxycodone DETERx
- Where
- 45 sites in United States
- Volunteers
- 740 people
- Sponsor
- Collegium Pharmaceutical, Inc.
Degenerative Disc Disease
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into…
- Trial name
- HyaluronicAcid (NCT06325566)
- Testing
- Rexlemestrocel-L + HA mixture, Saline
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- Mesoblast, Ltd.
Pain
Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation
The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
- Trial name
- NCT00412100
- Testing
- Oxycodone naloxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Patients With Taxane-induced Chronic Neuropathic Pain
Chemotherapy Induced Peripheral Neuropathy by Taxanes and Capsaicin 8%.
The goal of this study is to compare the evolution of the density of small nerve fibers assessed with skin biopsies at the foot between two groups of patients with taxane-induced chronic neuropathic pain matched for sex and age…
- Trial name
- capsaNeP (NCT07602387)
- Testing
- Capsaicin 8% Patch, antidepressants (tricyclics and serotonin reuptake inhibitor SRIs), antiepiletics, lidocaine patches, and neurostimulation
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospital Ambroise Paré Paris
Low Back Pain
Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
The objective of this study is to test the idea that the immediate-release (IR) form of tapentadol (CG5503) can be directly converted into an approximately equivalent total daily dose (TDD) of the extended-release (ER) form, and…
- Trial name
- NCT00594516
- Testing
- tapentadol (CG5503) Immediate Release IR, tapentadol (CG5503) Extended Release (ER), tapentadol (CG5503) Immediate Release (IR)
- Volunteers
- 117 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoarthritis
Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain
The purpose of this study is to evaluate the safety and efficacy of a single injection of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.
- Trial name
- NCT02558439
- Testing
- CNTX-4975
- Where
- 22 sites in United States
- Volunteers
- 175 people
- Sponsor
- Centrexion Therapeutics